On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve.

In the United States, where around 8 million people rely on insulin for diabetes management, soaring prices have created barriers to accessibility. As Congress takes initial steps to cap monthly ...

Pharmacy benefit managers received substantial attention during 2024. Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and related profits. As a new ...

Biosimilars trade groups and manufacturers have expressed concern about what they say are “unnecessary hurdles” present in the US Food and Drug Administration’s (FDA) recent draft guidance on ...

A biosimilar drug manufacturer is concentrating on process optimization to increase uptake of its products in lower-income countries. According to Jeffrey Hausfeld, MD, chairman of the board of ...

Tailored EMA and FDA pathways may waive comparative efficacy studies when analytical and functional similarity are convincingly demonstrated, while preserving clinical confirmation for ...

Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad ...

Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting. Biosimilars were a recurring subject at the Academy of Managed Care ...

Key Points Interested in Alvotech? Here are five stocks we like better. Alvotech says it is at an "inflection point," with ...

Novartis may be in the process of spinning out its generics and biosimilar outfit, Sandoz, but that doesn't mean the latter company is pausing manufacturing investments. In fact, it's quite the ...

Providers and patients who want to understand biosimilars can now navigate through a new web app, that was created by Prime, and delivered in partnership with the AMCP Foundation and Biosimilars ...